Invention Grant
- Patent Title: Inhibitor of the mutated isocitrate dehydrogenase IDH1 R132H
-
Application No.: US15748014Application Date: 2016-07-22
-
Publication No.: US10344004B2Publication Date: 2019-07-09
- Inventor: Heiko Schirmer
- Applicant: Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Berlin
- Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Berlin
- Agency: Morrison & Foerster LLP
- Priority: EP15178419 20150727
- International Application: PCT/EP2016/067477 WO 20160722
- International Announcement: WO2017/016992 WO 20170202
- Main IPC: C07D235/30
- IPC: C07D235/30 ; A61P35/00
Abstract:
The present invention relates to the adduct (2E)-but-2-enedioic acid-3-(2-{[4-(trifluoromethoxy)phenyl]amino}-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]-1H-benzimidazol-yl)propanoic acid (1:4), methods for preparing this adduct, pharmaceutical compositions comprising this adduct and also the use of this adduct for preparing a medicament for the treatment of a disease.
Public/Granted literature
- US20180222870A1 INHIBITOR OF THE MUTATED ISOCITRATE DEHYDROGENASE IDH1 R132H Public/Granted day:2018-08-09
Information query
